TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 875-882

  Giai, Maurizia ^a   Roagna, Riccardo ^a   Ponzone, Riccardo ^a   Biglia, Nicoletta ^a   Sgro, Luca ^a   Perona, Marco ^b   Sismondi, Piero ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

Breast cancer; CA 15.3; TPS; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; ESTROGEN RECEPTOR; GLYCOPROTEIN; PROGESTERONE RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN;

ARTICLE; BLOOD LEVEL; BREAST CANCER; BREAST DISEASE; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSKELETON; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MOLECULAR WEIGHT; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT PLANNING;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 0029939644     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3: 223-32, 1984.
2. Hilkens J, Buijs F, Hilgers J: Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 39: 197-206, 1984.
3. Pons-Anicet DMF, Krebs BP, Mira R, Namer M: Value of CA 15.3 in the follow up of breast cancer patients. Br J Cancer 55: 567-9, 1987.
4. Safi F, Koholer I, Rottinger E et al: The value of the tumor marker CA 15.3 in the diagnosis and monitoring of breast cancer. Cancer 68: 574-582, 1991.
5. Tondini C, Hayes DF, Gelman R, Henderson TC, Kufe DW: Comparison of CA 15.3 and Carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48: 4107-12, 1988.
6. Kallionemi OP, Oksa H, Aaran RK et al: Serum CA 15.3 assay in the diagnosis and follow up of breast cancer. Br J Cancer 58: 213-215, 1988.
7. Björklund B and Björklund V: Antigenicity of pooled human malignant and normal tissue by cytoimmunological technique, presence of a insoluble, heat labile tumor antigen. Int Arch Allergy 10: 153-184, 1957.
8. Björklund B: Tumor markers TPA, TPA-S, and cytokeratins. A working hypothesis. Tumordiagn Ther 13: 43-84, 1992.
9. Bonfrer MG, Groeneveld EM, Korse CM, van Dalen A, Oomen LCJM, Ivanyi D: Monoclonal antibody M used in TPS assay for the quantification of TPA recognises cytokeratin 18. Tumor Biol 15: 210-221, 1994.
10. van Dalen A TPS in breast cancer. A comparative study with carcinoembryonic antigen and CA 15.3. Tumor Biol 13: 10-17, 1992.
11. van Dalen A, van der Linde DL, Heering KJ, Elusse van Oudalblasr A: How can treatment response be measured in breast cancer patients? Anticancer Res 13: 1901-1904, 1993.
12. Pagnuzzi M, Bobbio B, Bruzzone M, Valenti G, Alama A, Merlo F, Onetto M: Comparison between tumor labeling index (TLI) and serum cell proliferation markers. J Tumor Marker Oncol 8: 63, 1993.
13. Gitsch G, Kainz C, Joura E, Fröhlich B, Bieglmayer C, Tatra G: Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and Tissue Polypeptide Specific Antigen in follow up of stage III cervical cancer. Anticancer Res 12: 1247-1250, 1992.
14. Björklund B: On the nature and clinical use oftissue polypeptide antigen. Tumor Diagnostik 1: 9-20, 1980.
15. Nemoto T, Constantine R, Chu TM: Human tissue polypeptide antigen in breast cancer. J Natl Cancer Inst 63: 1347-1350, 1979.
16. Eskelinen M, Hippeläinen M, Salmela E, Paajanen H, Alhava E, Syriänen K: A prospective study of tissue polypeptidic specific antigen (TPS) in breast cancer diagnosis. Anticancer Res 12: 2033-2036, 1992.
17. Anonymous: TNM Atlas: illustrated guide to the TNM/pTNM classification of malignant tumours. Third edition. Spiessl B et al. (eds) Springer, New York, 1989; 343
18. Bloom HIC, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359, 1957.
19. Thorpe SH: Steroid receptors: sources of interlaboratory variation in dextran charcoal assays. Breast Cancer Res Treat 9: 175-189, 1987.
20. Hayes DF: Tumor markers for breast cancer. Ann Oncol 4: 807-819, 1993.
21. Gion M, Mione R, Gatti C, Dittadi R, Leon A, Nascinben O, Pizzorno B, Bruscagnin G: Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA 15.3 and MCA. Tumori 76: 360-364, 1990.
22. Bathavdekar JM, Patel DD, Karelia NH, Vora HH, Nadkarni S, Ghosh N, Suthar TP, Balar DB. The clinical significance of Prolactin, TPS, CA 15.3 and CEA in patients with breast cancer. Breast Dis 6: 177-183, 1993.
23. Colomer, Ruibai A, Sahador I: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674-81, 1989.
24. Soletormos G, Nielsed D, Schioler V, Skovsgaard T, Winkel P, Mouridsen HT, Dombernowsky P: A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann Oncol 4: 861-869, 1993.
25. Ng JSY, Sturgeon CM, Paterson GM, Roulston JE, Leonard RCF: Serological markers for metastatic breast cancer. Dis Markers 11: 217-223, 1993.